Vanguard Group Inc. Raises Stock Holdings in Intellia Therapeutics, Inc. $NTLA

Key Points

• Vanguard Group Inc. has increased its holdings in Intellia Therapeutics by 5.5%, acquiring an additional 561,978 shares, bringing its total ownership to over 10 million shares valued at approximately $76 million.
• Recent analyst ratings on Intellia Therapeutics show a consensus of 12 Buy ratings, 6 Hold ratings, and 1 Sell rating, with a price target variance following several downward adjustments from firms like Royal Bank of Canada and Wells Fargo.
• Intellia Therapeutics reported a positive earnings surprise for the last quarter, with revenues of $14.25 million, exceeding analyst expectations, while still posting a loss of ($0.99) EPS.

Vanguard Group Inc. lifted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 5.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,752,031 shares of the company's stock after purchasing an additional 561,978 shares during the quarter. Vanguard Group Inc. owned about 10.38% of Intellia Therapeutics worth $76,447,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in shares of Intellia Therapeutics by 94.3% during the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 106,209 shares of the company's stock valued at $755,000 after purchasing an additional 51,552 shares in the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych boosted its holdings in Intellia Therapeutics by 30.6% in the first quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 81,000 shares of the company's stock worth $576,000 after acquiring an additional 19,000 shares in the last quarter. Privium Fund Management B.V. boosted its holdings in Intellia Therapeutics by 111.9% in the first quarter. Privium Fund Management B.V. now owns 58,709 shares of the company's stock worth $417,000 after acquiring an additional 31,000 shares in the last quarter. Harbour Investments Inc. boosted its holdings in Intellia Therapeutics by 76.7% in the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock worth $37,000 after acquiring an additional 2,264 shares in the last quarter. Finally, XTX Topco Ltd boosted its holdings in Intellia Therapeutics by 84.2% in the first quarter. XTX Topco Ltd now owns 80,897 shares of the company's stock worth $575,000 after acquiring an additional 36,989 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock traded down $0.02 during mid-day trading on Tuesday, reaching $11.36. 3,395,953 shares of the stock traded hands, compared to its average volume of 4,746,083. The stock has a market capitalization of $1.22 billion, a PE ratio of -2.42 and a beta of 2.31. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $23.76. The business's 50-day moving average is $11.16 and its 200-day moving average is $9.54.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, beating analysts' consensus estimates of ($1.03) by $0.04. The company had revenue of $14.25 million during the quarter, compared to analysts' expectations of $12.26 million. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.Intellia Therapeutics's revenue for the quarter was up 104.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.52) earnings per share. Equities analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Wells Fargo & Company reissued an "overweight" rating and issued a $45.00 target price (down from $50.00) on shares of Intellia Therapeutics in a report on Friday, August 8th. Wedbush restated a "neutral" rating and issued a $7.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 16th. Royal Bank Of Canada decreased their price target on Intellia Therapeutics from $25.00 to $21.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. Chardan Capital decreased their price target on Intellia Therapeutics from $68.00 to $60.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Finally, Canaccord Genuity Group decreased their price target on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a research note on Tuesday, June 3rd. Twelve investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $29.05.

Insider Transactions at Intellia Therapeutics

In related news, Director William J. Chase purchased 100,000 shares of Intellia Therapeutics stock in a transaction on Wednesday, August 20th. The stock was acquired at an average price of $10.03 per share, for a total transaction of $1,003,000.00. Following the completion of the transaction, the director directly owned 134,693 shares in the company, valued at $1,350,970.79. This represents a 288.24% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Edward J. Dulac III sold 7,462 shares of the company's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total value of $104,617.24. Following the completion of the sale, the executive vice president owned 106,062 shares of the company's stock, valued at approximately $1,486,989.24. The trade was a 6.57% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 12,534 shares of company stock valued at $153,837. Company insiders own 3.10% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.